Privia Health Pivots to Scalable Margin Expansion as AI and New Markets Fuel a Confident Guidance Raise
Q2 2026 results show strong double-digit growth, a 310bp EBITDA margin lift, and a raised outlook — but the stock remains in a deep drawdown, leaving investors to weigh execution against valuation.
PRVA · Earnings Call · 2026-08-06
A Quarter of Visible Operating Leverage
Privia Health reported a robust Q2 2026, with practice collections up 12.4% year-over-year and adjusted EBITDA up 29%, translating to a 310 basis point margin expansion as a percentage of care margin. Management was notably confident, raising its full-year outlook across all key metrics. The company's longstanding focus on cost of platform leverage — the single largest driver of its EBITDA growth story — was again on display, with cost of platform scaling to 52.5% of care margin, down 400bps from a year ago. CFO David Mountcastle attributed this to a combination of technology spend discipline and operational scaling across practice operations.
We are continuing our journey to deploy AI applications in various workflows across the organization and expect to continue to expand our EBITDA margin towards the high end of our long-term target range of 30% to 35% of care margin over the next few years.
The AI narrative is becoming a tangible margin lever, not just a talking point. Parth Mehrotra detailed four core workflows — corporate functions, fee-for-service, value-based, and patient care — where AI adoption is being measured at a “micro level” against time saved and cost avoided. This is a natural evolution from prior quarters, where the company first flagged AI as a potential margin driver, but now the incremental confidence to push toward the high end of the range is new and meaningful.
New Markets, Rising Attributed Lives, and a Growing National Footprint
Privia entered New Jersey in late May, its 25th state, and has guided to adding 570 implemented providers this year, a 10.6% increase. Implemented providers grew 10.1% year-over-year, while value-based attributed lives grew a strong 19.2%. The company's patient panel now spans over 6.1 million patients. Management emphasized that same-store growth remains a key driver — a point reinforced in Q&A, where Parth noted that existing practices are “the best salespeople.”
In the Q&A, David Mountcastle reiterated the predictability of the business, saying that by the time annual guidance is given, “90% of the business is pretty much locked in on a fee-for-service basis.” That visibility supports the confidence around the raised 2026 outlook, even as the stock trades down over the past year.
“If you see our guidance, we expect to be 29% this year EBITDA to care margin. So it's pretty much very close to the 30%.” — David Mountcastle, Chief Financial Officer · 2026-08-06
The company also pointed to a robust business development pipeline, with the Care Partners (Evolent) acquisition opening up an ACO-only model that expands the addressable TAM beyond the full medical group. This two-pronged go-to-market strategy is still early but could be a meaningful long-term growth vector.
Shared Savings and Government Tailwinds
A significant portion of the conversation focused on the Medicare Shared Savings Program (MSSP). CMS has proposed retroactive changes for performance year 2025, potentially delaying final reconciliation and cash settlements. Parth downplayed the impact, saying in the Q&A:
“We don't see any issues in receiving the money. I think whether it comes early November, late November, December, it will happen when it happens, but I don't think it's a big concern for us.” — Parth Mehrotra, Chief Executive Officer · 2026-08-06
Notably, the company raised its guidance partly because of positive expected outcomes from MSSP changes, and management sees these as a step in the right direction for community-based providers. This is a slightly new tone — prior calls were more cautious about programmatic shifts, but now with the proposed changes appearing favorable, the company is leaning into the tailwind.
Financial Underpinnings and Valuation
On a full-year basis, revenue growth remains strong — Total Revenue grew 26% year-over-year in the latest quarter, but net income was just $4M, reflecting continued investment in growth. The company's balance sheet is clean, with over $412M in cash and no debt. Yet the stock remains deep in the red, with a full-history drawdown of over 57% from its 2021 peak and a recent 90-day decline of 5.6%. This disconnect between fundamental execution and price action suggests investors are still pricing in risk around the value-based care model and the broader government-payer exposure.
The bias toward shared savings and the high visibility of provider additions make the stock's performance hard to explain on fundamentals alone. As management noted, the company is “one of the survivors” in the industry, and its ability to double EBITDA on a rolling three-year basis is a testament to the AI applications in various workflows and operational discipline.
What’s Changed?
The biggest shift this quarter is the explicit confidence in reaching the high end of the long-term margin target through AI and scaling, the entrance into a new major market, and the decision to raise guidance despite a delayed CMS settlement. The company is no longer just talking about potential — it’s demonstrating measurable operating leverage. For investors, the question is whether the market will finally reward a company that continues to compound at a 20%+ EBITDA growth rate while trading at a discount to its historical multiples.